Rare diseases, also known as orphan diseases, affect an estimated 300 million people worldwide, yet each individual condition impacts a relatively small patient popu...

Committees (DMCs) has never been more critical in ensuring patient safety and trial integrity, especially as clinical trials become more complex and globalised. In r...

The discovery and integration of cancer biomarkers into oncology research has transformed how cancer is detected, diagnosed and treated. As precision medicine contin...

The need for a UK national screening programme to enable early detection of prostate cancer is now more important than ever, with one in six men receiving a prostate...

 Data in life sciences is more than a mere byproduct of research; it is a driving force behind innovation. By harnessing extensive datasets, organisations can s...

By 2026, IDMP compliance will become more challenging for all pharmaceutical companies operating in the EU, due to the broader adoption of the IDMP data model. Now, ...

Deep learning technology can be very strong at identifying complex patterns within large data sets and mapping them to simple classifications like diagnosing a certa...

Rare disease clinical trials face a confluence of challenges: limited patient populations, heterogeneity in disease progression, and often a lack of established outc...

Who better to shape clinical research in rare disease than those living with the conditions. Patient and public involvement in clinical research is crucial for ensur...

Rare diseases, which affect >30 million individuals in the United States (US), have historically taken a back seat to more common diseases such as cancer, diabete...